Zymeworks
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 277
- Market Cap
- $822M
- Introduction
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Zymeworks Inc. (ZYME) Stock Price, News, Quote & History
Zymeworks Inc. (ZYME), a biopharmaceutical company, focuses on cancer treatment through biotherapeutics. Key products include zanidatamab and zanidatamab zovodotin, targeting HER2 in various clinical trial phases. With strategic partnerships and a market cap of $973.239M, ZYME is advancing in oncology and immuno-oncology, despite a negative EPS of -1.49 and a profit margin of -182.75%.
Boehringer Ingelheim Acquires Fourth License for Novel Oncology Target
Oxford BioTherapeutics (OBT) announced Boehringer Ingelheim exercised an option for a fourth novel oncology target discovered using OBT's OGAP® platform, triggering a milestone payment. This collaboration aims to develop next-generation cancer immunotherapies, with Boehringer Ingelheim responsible for future development and commercialization, and OBT receiving milestone payments and royalties.
Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics
Oxford BioTherapeutics (OBT) announced Boehringer Ingelheim exercised an option for a fourth novel oncology target from their collaboration, discovered using OBT's OGAP® platform. This triggers a milestone payment to OBT, with Boehringer Ingelheim responsible for future development and commercialization. OBT's OGAP® platform enhances target selection for therapeutic antibodies, with three programs in clinical development.
Zymeworks (ZYME) Receives a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Stephen Willey maintains a Buy rating on Zymeworks (ZYME) with a $28.00 price target, up from yesterday's close at $14.13. Zymeworks, a biopharmaceutical company, focuses on biotherapeutics development, including ZW25 and ZW49 bispecific antibodies. Market cap: $981.3M; P/E: -9.37.
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
Zymeworks anticipates IND applications for ZW220 and ZW251 in 2025, and for ZW209 and ZW1528 in 2026. Phase 3 results for Ziihera® in HER2-positive GEA expected 2Q-2025, with potential sBLA submission. Regulatory decisions for zanidatamab in BTC in EU and China as early as 2Q-2025. $324M cash as of Dec 31, 2024, with runway into 2H-2027. Expanding R&D into AIID and hematological cancers.
Liberty Defense's HEXWAVE System Selected for Trial in Middle Eastern US Ally, K92 Mining Reports Record Production
Liberty Defense's HEXWAVE system selected for a trial in a Middle Eastern US ally to detect explosive threats, including metallic and non-metallic materials, for border security, check-points, and military applications. K92 Mining reports record Q4 and annual production, exceeding guidance, with high metallurgical recoveries and increased mine development rates.
Zymeworks Inc. (ZYME) Latest Press Releases & Strategic Priorities
Zymeworks outlines strategic priorities, anticipating IND applications for ZW220 and ZW251 in 2025, and ZW209 and ZW1528 in 2026. Ziihera® receives FDA approval for HER2-positive BTC, with a $25M milestone from Jazz Pharmaceuticals. Zymeworks progresses in oncology, autoimmune diseases, and reports financial updates, highlighting clinical advancements and regulatory milestones.
Zymeworks Sets Strategic Milestones for 2025-2026 with New Drug Applications and Clinical Trial Results
Zymeworks outlines 2025-2026 strategic priorities, including new drug applications for solid tumor treatments, expecting regulatory decisions and clinical trial results. With FDA-approved zanidatamab and a strong financial outlook, it aims to expand into autoimmune, inflammatory diseases, and hematological cancers.
© Copyright 2025. All Rights Reserved by MedPath